Clinical trials: Blood Plasma Therapy
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Blood Cancer, Lymphoma
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function.
- Conditions
- Blood Cancer, Lymphoma, Leukemia, Myeloma
- Trial name
- NCT07052916
- Testing
- Music Therapy/MT, Therapist-Attention Music Education/TAME Control
- Where
- 7 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Onychomycosis
Evaluating the Safety, Tolerability and Preliminary Efficacy of Plasma in Improving the Appearance of Onychomycosis
The purpose of this study is to evaluate the safety and preliminary efficacy of using electrical plasma to treat toenail fungus.
- Trial name
- NCT02724384
- Testing
- MOE Plasma Delivery System A, MOE Plasma Delivery System B
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Moe Medical Devices
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
This phase I trial studies the side effects and best dose of monoclonal antibody therapy before stem cell transplant in treating patients with relapsed or refractory lymphoid malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01678443
- Testing
- indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
Background: Smoldering multiple myeloma (SMM) is a condition that can lead to multiple myeloma, a type of blood cancer. In many high-risk cases, SMM can develop into multiple myeloma in less than 2 years.
- Trial name
- NCT01660997
- Testing
- MLN9708, Dexamethasone
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Collecting and Storing Blood Samples From Patients With Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00900120
- Sponsor
- University of Medicine and Dentistry of New Jersey
Post-COVID19 Condition
Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study
PAX is a prospective, randomized (1:1), double-blind, placebo-controlled study, that have as a objective to evaluate the safety and tolerability of plasma exchange (PE) in patients with Post Acute Covid-19 Syndrome (PCC)…
- Trial name
- NCT05445674
- Testing
- Plasma Exchange Procedure
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Multiple Myeloma, Relapsed Cancer
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease
- Trial name
- NCT05641324
- Testing
- ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 4 people
- Sponsor
- Anaveon AG
AML, ALL
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Allogeneic stem cell transplantation may provide long-term remissions for some patients with hematological malignancies. However, allogeneic transplantation is associated with a significant risk of potentially life threatening…
- Conditions
- AML, ALL, CLL, Myelodysplastic Syndrome
- Trial name
- NCT00533923
- Testing
- Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Multiple Myeloma, Minimal Residual Disease
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
The goal of this observational study is to compare the efficacy and safety of autologous hematopoietic stem-cell transplantation (ASCT) versus non ASCT regimens in primary multiple myeloma patients achieved MRD negativity after…
- Trial name
- NCT06463717
- Testing
- Transplant, Autologous, Chemotherapy drug
- Where
- China
- Volunteers
- 210 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Myeloma
Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
The main goal of the project is to characterize the bone marrow immunological milieu and investigate potential treatment defining events of the tumor microenvironment in relapsed and refractory multiple myeloma (RRMM) patients…
- Trial name
- IMPACT (NCT07878208)
- Where
- 7 sites in Denmark, Norway
- Volunteers
- 50 people
- Sponsor
- Odense University Hospital
Urinary Incontinence, Stress Urinary Incontinence
Platelet Rich Plasma in Women With Urinary Incontinence
Stress urinary incontinence (SUI) is defined as involuntary loss of urine on effort or physical exertion or on sneezing or coughing.
- Trial name
- NCT05112718
- Testing
- Platelet Rich Plasma Injections, Normal Saline Injections
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- National and Kapodistrian University of Athens
Plasma Cell Myeloma, Secondary Amyloidosis
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
- Trial name
- NCT03346135
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Dengue Fever, Pleural Effusion
Ketotifen as a Treatment for Vascular Leakage During Dengue Fever
Rationale and Aims: Infection by dengue virus (DENV) causes major morbidity and mortality throughout the world. In 2012, an estimated 3.6 billion people live in areas at risk for DENV infection, including Singapore.
- Trial name
- KETODEN (NCT02673840)
- Testing
- Ketotifen
- Where
- 2 sites in Singapore
- Volunteers
- 110 people
- Sponsor
- National University Hospital, Singapore
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
This phase II MATCH treatment trial identifies the effects of AZD4547 in patients whose cancer has genetic changes called FGFR gene alterations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439240
- Testing
- FGFR Inhibitor AZD4547
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Androgenic Alopecia
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.
- Trial name
- NCT03474718
- Testing
- Platelet-rich Plasma Left Side, Platelet-rich Plasma Right Side
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Acute Leukemia, Chronic Leukemia
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
In an attempt to reduce relapse risk and improve outcomes following haploidentical transplantation for patients with high risk hematologic malignancies, the investigators will implement several strategies to augment the well…
- Conditions
- Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas
- Trial name
- NCT02169791
- Testing
- MLN9708
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Northside Hospital, Inc.
Stress Incontinence, Female
PRP & PDO Threads in Treatment of Stress Incontinence
The study will include 10 women with pure or predominant SUI symptoms, with severe urodynamic stress incontinence on urodynamics defined as loss of urine with sudden increases in abdominal pressure: eg, coughing, sneezing, or…
- Trial name
- NCT06885463
- Testing
- platelets rich plasma combined with PDO threads
- Where
- Egypt
- Volunteers
- 10 people
- Sponsor
- Al-Azhar University
Relapsed or Refractory Multiple Myeloma
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
- Trial name
- NCT03751293
- Testing
- C-CAR088
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Multiple Myeloma
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
The purpose of this phase II study is to assess the toxicity and efficacy of sequentially administered high dose chemotherapy followed by autologous stem cell rescue in the treatment of multiple myeloma.
- Trial name
- NCT00586014
- Testing
- High-Dose Sequential Chemotherapy followed by ASCT
- Volunteers
- 91 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.